| abstract |
(57) [Summary] [Purpose] To provide a novel antitumor agent. An antitumor agent comprising a combination of a fumagillol derivative having angiogenesis inhibitory activity or a salt thereof and an antimetabolite anticancer substance, and a preparation and an antimetabolite comprising the fumagillol derivative having angiogenesis inhibitory activity or a salt thereof A tumor treatment kit for combined administration, which is characterized in that a preparation comprising a type 2 anti-cancer substance is set as a set. [Effect] It is useful for the treatment of mammals having a tumor, has a remarkable effect in prolonging the life of cancer-bearing animals and suppressing cancer metastasis, and has high safety and clinical utility. |